TITLE

PAF63 High prevalence of distal sensory polyneuropathy in treated and untreated Tanzanians with HIV. A cross-sectional survey

AUTHOR(S)
S Mullin
PUB. DATE
November 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Distal sensory polyneuropathy (DSP) is a well-known complication both of advanced HIV disease and of antiretroviral treatments (ARTs), in particular stavudine and didanosone. Both are widely used in sub-Saharan Africa. There are few data documenting the prevalence of HIV DSP in African settings. AIM: To describe the prevalence of DSP among Tanzanian patients with HIV, on and off ART and with CD4 counts above and below 200x106/l. We recruited HIV-positive clinic attendees into four groups: >6 months ART exposure and (i) CD4200 cells/µl; ART naïve and (iii) CD4200 cells/µl. Primary outcome was DSP as defined by presence of at least one symptom and one clinical sign elicited with the ACTG screening tool for DSP. RESULTS: 335 subjects were recruited. Nine were excluded. Subject numbers were 81 (ART200), 81 (noART/200). Prevalences of DSP in each group were ((ART/200) 41.3% (% CI 30.5 to 53.5)). ((noART/200) 20.9% (% CI 12.0 to 29.4)). CONCLUSION: HIV DSP is frequently present even amongst otherwise largely asymptomatic patients. Stavudine and didanosone expose HIV patients to an avoidable risk of DSP with significant morbidity and an impaired quality of life. Diagnosis and management of DSP is inadequate. Access to nonneurotoxic ART regimes as well as earlier diagnosis and initiation of ART is needed.
ACCESSION #
54845725

 

Related Articles

  • Differential Treatment. ZAIDI, SARAH // UN Chronicle;2011, Vol. 48 Issue 1, p26 

    The article focuses on the gap in the access to antiretroviral (ARV) treatment to HIV/AIDS patients between industrialized and developing countries. It mentions the need of people living with HIV (PLHIV) to gain constant access to newer drugs for better quality of life and compares the high cost...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study. Panos, George; Samonis, George; Alexiou, Vangelis G.; Kavarnou, Garyfallia A.; Charatsis, Gerasimos; Falagas, Matthew E. // Current HIV Research;May2008, Vol. 6 Issue 3, p257 

    HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987-2006). The study was divided in pre-HAART and HAART period for...

  • Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection. Gentz, Mark; Levin, Todd P.; Klibanov, Olga M.; Feingold, Anat; Condoluci, David V. // AIDS Patient Care & STDs;Nov2006, Vol. 20 Issue 11, p741 

    Antiretroviral resistance in treatment-naïve patients with HIV-1 infection is on the rise in both resource-rich and resource-poor countries. We report a case of three-class primary antiretroviral resistance detected by a genotypic assay in a 19-year-old woman with acute HIV-1 infection. Her...

  • Modelling T4 cell count as a marker of HIV progression in the absence of any defense mechanism. Yadavalli, Venkata S. Sarma; Labeodan, Moremi Morire OreOluwapo; Udayabaskaran, Swaminathan; Forche, N. // Orion;2010, Vol. 26 Issue 2, p113 

    The T4 cell count, which is considered one of the markers of disease progression in an HIV infected individual, is modelled in this paper. The World Health Organisation has recently advocated that countries encourage HIV infected individuals to commence antiretroviral treatments once their T4...

  • HIV-Induced T-Cell Activation/Exhaustion in Rectal Mucosa Is Controlled Only Partially by Antiretroviral Treatment. Rueda, Cesar Mauricio; Velilla, Paula Andrea; Chougnet, Claire A.; Montoya, Carlos Julio; Rugeles, Maria Teresa // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Peripheral blood T-cells from untreated HIV-1-infected patients exhibit reduced immune responses, usually associated with a hyperactivated/exhausted phenotype compared to HAART treated patients. However, it is not clear whether HAART ameliorates this altered phenotype of T-cells in the...

  • Antiretroviral prescribing delayed among certain patients.  // PharmacoEconomics & Outcomes News;4/24/2004, Issue 451, p7 

    Discusses a study conducted by researchers in the U.S. in April 2004, which revealed the delay of antiretroviral therapy for nonadherent HIV-infected patients caused by physicians who follow guidelines on antiretroviral treatment. Number of patients with HIV infections that were evaluated;...

  • Prevalence of intestinal parasites in relation to CD4 counts and anaemia among HIV-infected patients in Benin City, Edo State, Nigeria. Akinbo, Frederick O.; Okaka, Christopher E.; Omoregie, Richard // Tanzania Journal of Health Research;Feb2011, Vol. 13 Issue 1, p10 

    Parasitic infections continue to take their toll on HIV positive patients by influencing the blood qualitatively and quantitatively. The objective of this study was to determine the prevalence of intestinal parasitic infections in relation to anaemia and CD4 counts among HIV-infected patients in...

  • Partner protection. Coghlan, Andy // New Scientist;4/28/2012, Vol. 214 Issue 2862, p4 

    The article discusses a recommendation from the World Health Organization (WHO) to immediately give any person with HIV, whose partner is not infected, antiretroviral drugs to prevent HIV transmission.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics